Today's post is shared from techtime.com/ A new gadget revealed at CES 2015 promises to provide pain relief through technology. The device, dubbed Quell, attaches to the user's calf and stimulates the body's opiate production to relieve pain from various ailments. When most people think of pain relief, they think of some sort of pill ingested internally, such as aspirin, ibuprofen, naproxen, or similar over the counter product. For more serious pain, there are prescription medicines available, but they can be highly addictive, have many serious side effects, and have a large potential for abuse. Quell promises an external source of pain relief. The unit attaches to the user's calf, which the makers of the Quell consider a "virtual USB port," and electrodes stimulate the wearer's body to release pain-relieving opiates. The sensory nerves it stimulates send neural pulses to the brain that trigger the release of endogenous opioids, the pain-relief response that blocks pain signals in the spine. The process is called Transcutaneous Electrical Nerve Stimulation technology, also known as TENS. There are already over-the-counter TENS systems such as the one made by Icy Hot, but these are very low-powered and low-tech compared with Quell. Quell is also much more expensive, but manufacturer NeuroMetrix, a health-care company that develops... [Click here to see the rest of this post] |
The findings echo the conclusions of two other reports released last week by major pharmacy benefit managers, which predicted that spending on so-called specialty drugs would continue to rise.
The report, by the IMS Institute for Healthcare Informatics, also found that consumers’ use of health care — visits to the doctor, hospital admissions and prescription drug use — rose in 2013 for the first time in three years, mainly because of the improving economy, it said.
“Following several years of decline, 2013 was striking for the increased use by patients of all parts of the U.S. health care system,” Murray Aitken, executive director of the IMS Institute, said in a statement. He noted that the spike came before the Affordable Care Act, which has helped provide health insurance to millions of new customers, fully went into effect.
But even as consumers became more confident about spending money on health care last year, the report found that a divide is developing between those with medical conditions that can be treated with cheap generic drugs, and those with rare and often more serious diseases that can come with breathtaking price tags.
More than...